Sophie Harris, Neel Basudev, and Faye Edwards from the Health Innovation Network South London reflect on their key takeaways from the 2025 Diabetes UK Professional Conference. They explore how the latest innovations and evidence align with the NHS’s three shifts, highlighting the potential to transform diabetes prevention and care across south London and beyond.
The Diabetes UK Professional Conference (DUK) is a pivotal event in the diabetes calendar, bringing together healthcare professionals, researchers, people with lived experience, and system leaders to share insights and best practices. Held this year in a remarkably sunny Glasgow from 26-28 February, the conference showcased the latest developments in diabetes care, treatment, and research.
The Health Innovation Network (HIN) South London team was well represented, contributing to discussions and presenting work that reflects the commitment of south London colleagues to improving outcomes for people living with diabetes. Among the contributions were three poster presentations focused on improving communication and data sharing in gestational diabetes, learning from those with early onset type 2 diabetes, and developing a
As Diabetes Clinical Directors for the HIN and a Senior Programme Manager, we attended the conference to engage with the latest thinking, evidence, and innovations in diabetes care. This blog shares our reflections, viewed through the lens of the NHS’s three shifts: moving care from hospitals to communities, making better use of technology, and focusing on preventing sickness rather than just treating it. These themes provide a valuable framework to consider how diabetes services can evolve to meet current and future challenges.
Moving care from hospitals to communities
A central theme at this year’s conference was the growing emphasis on shifting care closer to home. This aligns with the NHS’s ambition to reduce reliance on hospital services and strengthen community-based care.
Our recent work on gestational diabetes was highlighted as a case study in a session on midwifery and nursing. Our standardised approach to diabetes data standards and clinical coding in primary care was cited as an example of how system-wide consistency can improve outcomes for pregnant women. This was a proud moment, demonstrating how local initiatives can have national relevance.
The importance of peer support also featured prominently. Several sessions explored how peer support workers are being embedded within diabetes care teams, providing invaluable lived experience and non-clinical guidance. Youth workers, in particular, are being employed to engage young people with type 1 and type 2 diabetes. These roles are critical in promoting lifestyle interventions, exercise, and weight management in ways that resonate with younger populations. However, while the benefits are clear, articulating the full impact of peer support to commissioners remains a challenge, as many of the outcomes are nuanced and not easily captured through traditional clinical metrics.
Making better use of technology
The rapid pace of technological innovation was a defining feature of the conference. Hybrid Closed Loop (HCL) technology and Continuous Glucose Monitoring (CGM) are transforming care for people living with type 1 diabetes. The implementation of NICE Guidance TA943 was celebrated as a success, with year one seeing a marked increase in access to HCL systems for children and young people, and equitable uptake across most demographics. The Scottish team’s remote onboarding approach was particularly inspiring, demonstrating that small, centralised teams can successfully scale access to life-changing technology.
Despite these successes, there are areas where the adoption of technology remains complex. For people with type 2 diabetes, the role of CGM and similar technologies is less defined. Challenges around the evidence base, scalability, and cost were cited. Nonetheless, technological advances such as predictive workforce modelling and personalised medication regimens – including a novel five-drug model based on patient demographics – offer a glimpse into a future of truly tailored care.
Focusing on preventing sickness, not just treating it
The need to shift focus towards prevention and early intervention was a strong thread throughout the conference. Early onset type 2 diabetes received considerable attention, with speakers sharing the importance of multidisciplinary teams delivering rapid, holistic interventions aimed at remission. This approach includes access to psychological and peer support, CGM technology, structured education, weight management medications, and preconception and pregnancy care.
Screening and early intervention for type 1 diabetes were also discussed in depth. The ELSA and T1DRA studies demonstrated the feasibility and benefits of early identification through antibody testing. However, simply knowing one’s risk is not enough. Continuous monitoring and, in time, immunotherapies offer new hope for delaying progression to insulin-dependent diabetes. As immunotherapies begin to move into clinical practice in other health systems, there is a clear opportunity, and responsibility, for the NHS to prepare for their adoption.
Meanwhile, the rise of weight management medications like Mounjaro (tirzepatide) remains a hot topic. With significant outcomes, including up to 86% of individuals achieving at least 10% body weight loss, there is enormous potential for these therapies in diabetes prevention and treatment. However, concerns about affordability and prioritisation continue to pose questions for commissioners and policy-makers alike.
Looking forwards
The Diabetes UK Professional Conference 2025 reaffirmed the need for continued innovation, collaboration, and system transformation in diabetes care. Whether through technology, workforce models, peer support, or personalised medicine, the solutions showcased offer tangible ways to align with the NHS’s three shifts and drive better outcomes for people living with diabetes.
For the HIN South London, the conference has reinforced our focus on supporting the implementation of HCL technology, embedding peer support and youth workers in diabetes care pathways, and advancing work on early onset type 2 diabetes. We are also closely monitoring developments in immunotherapy and weight management medications to ensure south London is ready to adopt these interventions in a way that delivers equity and value.
As we look to the future, we remain committed to championing innovations that move care closer to people’s lives, harness technology to improve outcomes, and prioritise prevention to create a healthier south London. We look forward to sharing more at next year’s conference in Liverpool.